MCID: MNT001
MIFTS: 73

Mantle Cell Lymphoma

Categories: Rare diseases, Cancer diseases, Blood diseases, Immune diseases

Aliases & Classifications for Mantle Cell Lymphoma

MalaCards integrated aliases for Mantle Cell Lymphoma:

Name: Mantle Cell Lymphoma 38 12 76 53 59 37 29 6 15
Lymphoma, Mantle Cell 53 13
Malignant Lymphoma, Lymphocytic, Intermediate Differentiation, Diffuse 73
Malignant Lymphoma - Lymphocytic, Intermediate Differentiation 73
Lymphoma, Mantle-Cell 44
Mantle Zone Lymphoma 59
Lymphoma Mantle-Cell 55
Mcl 59
Lcm 59

Characteristics:

Orphanet epidemiological data:

59
mantle cell lymphoma
Inheritance: Multigenic/multifactorial,Not applicable; Prevalence: 1-9/1000000 (United States),1-9/100000 (Europe),1-9/100000 (France); Age of onset: Adult; Age of death: adult;

Classifications:



External Ids:

Disease Ontology 12 DOID:0050746
MeSH 44 D020522
Orphanet 59 ORPHA52416
MESH via Orphanet 45 D020522
ICD10 via Orphanet 34 C83.1
UMLS via Orphanet 74 C0555202
KEGG 37 H01464
ICD10 33 C83.1

Summaries for Mantle Cell Lymphoma

NIH Rare Diseases : 53 Mantle cell lymphoma (MCL) belongs to a group of diseases known as non-Hodgkin’s lymphomas (NHL). NHL's are cancers that affect the the lymphatic system (part of the immune system). In MCL, there are cancerous B-cells (a type of immune system cell). The cancerous B-cells are within a region of the lymph node known as the mantle zone. Although MCLs are slow-growing cancers, the cancer is usually widespread by the time it is diagnosed. In these situations, treatment must be intensive since MCL can become life threatening within a short period of time. MCL accounts for 6% of all NHL's and is mostly found in males during their early 60s.

MalaCards based summary : Mantle Cell Lymphoma, also known as lymphoma, mantle cell, is related to follicular lymphoma and lymphoma. An important gene associated with Mantle Cell Lymphoma is ATM (ATM Serine/Threonine Kinase), and among its related pathways/superpathways are PI3K-Akt signaling pathway and Endometrial cancer. The drugs Imbruvica and Revlimid have been mentioned in the context of this disorder. Affiliated tissues include b cells, bone and bone marrow, and related phenotypes are splenomegaly and weight loss

Disease Ontology : 12 A B-cell lymphocytic neoplasm due to CD5 positive antigen-naive pregerminal center B-cell within the mantle zone that surrounds normal germinal center follicles.

Wikipedia : 76 Mantle cell lymphoma (MCL) is a type of non-Hodgkin\'s lymphoma (NHL), comprising about 6% of NHL cases.... more...

Related Diseases for Mantle Cell Lymphoma

Diseases related to Mantle Cell Lymphoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 202)
# Related Disease Score Top Affiliating Genes
1 follicular lymphoma 32.8 BCL2 BCL6 CCND1 IGH MCL1 MME
2 lymphoma 31.9 ATM BCL2 BCL6 CCND1 EZH2 GAS5
3 prolymphocytic leukemia 31.5 ATM CCND1 CD5 MYC
4 composite lymphoma 31.5 BCL6 CD5 SOX11
5 marginal zone b-cell lymphoma 31.3 BCL2 BCL6 CD5 MME
6 b cell prolymphocytic leukemia 31.3 CD5 MYC TP53
7 follicular lymphoma 1 31.1 BCL2 BCL6 IGH
8 cll/sll 31.0 ATM CCND1 CD5 MME SOX11 TP53
9 peripheral t-cell lymphoma 31.0 BCL6 CD5 MME TP53
10 diffuse large b-cell lymphoma 30.9 BCL6 CD5 EZH2 MDM2 MME MYC
11 leukemia, chronic lymphocytic 30.8 ATM BCL2 BCL6 CCND1 CCND2 CD5
12 lymphoblastic lymphoma 30.8 BCL6 CD5 MME
13 lymphoma, mucosa-associated lymphoid type 30.7 BCL2 BCL6 CCND1 CD5 IGH MME
14 retinoblastoma 30.6 CCND1 MALAT1 MDM2 TP53
15 pancreas adenocarcinoma 30.3 CCND1 MYC TP53
16 leukemia, acute myeloid 30.2 EZH2 MALAT1 MCL1 MME MYC TP53
17 lymphoma, non-hodgkin, familial 30.1 ATM BCL2 BCL6 CCND1 CCND2 CD5
18 myeloma, multiple 30.1 CCND1 CCND2 GAS5 MALAT1 MCL1 MYC
19 lung cancer susceptibility 3 29.8 CCND1 GAS5 MALAT1 TP53
20 bladder cancer 29.4 CCND1 EZH2 GAS5 MALAT1 MDM2 MYC
21 b-cell lymphomas 29.4 BCL2 BCL6 BTK CCND1 CCND2 CD5
22 colorectal cancer 28.9 ATM BCL2 CCND1 CCND2 GAS5 MALAT1
23 breast cancer 28.8 ATM BCL2 CCND1 CCND2 EZH2 GAS5
24 prostate cancer 28.7 BCL2 CCND1 EZH2 GAS5 MALAT1 MCL1
25 lymphoma, small cleaved-cell, diffuse 11.2 BCL2 CCND1
26 diffuse large b-cell lymphoma of the central nervous system 11.2 BCL2 MYC
27 synchronous bilateral breast carcinoma 11.2 ATM CCND1 TP53
28 ring chromosome 7 11.2 MDM2 TP53
29 zika virus infection 11.2 MDM2 TP53
30 hidradenocarcinoma 11.1 BCL2 CCND1 TP53
31 keratocystic odontogenic tumor 11.1 BCL2 CCND1 TP53
32 suppressor of tumorigenicity 3 11.1 BCL2 MYC TP53
33 myxosarcoma 11.1 ATM MDM2 TP53
34 soft tissue sarcoma 11.1 BCL2 MDM2 TP53
35 ectopic thymus 11.1 BCL2 CD5
36 nodal marginal zone b-cell lymphoma 11.1 BCL2 BCL6
37 tracheal lymphoma 11.1 CD5 MME
38 high grade b-cell lymphoma with myc and/ or bcl2 and/or bcl6 rearrangement 11.0 BCL2 BCL6 MYC
39 richter's syndrome 11.0 ATM CD5 MYC TP53
40 inflammatory myofibroblastic tumor 11.0 CCND1 MDM2 TP53
41 male reproductive organ cancer 11.0 CCND1 MYC TP53
42 female reproductive organ cancer 11.0 CCND1 MYC TP53
43 ocular cancer 11.0 CCND1 MDM2 MYC TP53
44 li-fraumeni syndrome 11.0 ATM BCL2 MDM2 TP53
45 nervous system cancer 11.0 CCND1 MDM2 MYC TP53
46 gastric lymphoma 11.0 BCL2 BCL6 TP53
47 bile duct carcinoma 11.0 CCND1 MYC TP53
48 dendritic cell thymoma 11.0 BCL2 CD5
49 cervical carcinosarcoma 11.0 BCL2 MME TP53
50 epidural neoplasm 11.0 BCL6 CD5 TP53

Graphical network of the top 20 diseases related to Mantle Cell Lymphoma:



Diseases related to Mantle Cell Lymphoma

Symptoms & Phenotypes for Mantle Cell Lymphoma

Human phenotypes related to Mantle Cell Lymphoma:

59 32 (show all 9)
# Description HPO Frequency Orphanet Frequency HPO Source Accession
1 splenomegaly 59 32 frequent (33%) Frequent (79-30%) HP:0001744
2 weight loss 59 32 frequent (33%) Frequent (79-30%) HP:0001824
3 anorexia 59 32 frequent (33%) Frequent (79-30%) HP:0002039
4 lymphadenopathy 59 32 hallmark (90%) Very frequent (99-80%) HP:0002716
5 abnormality of bone marrow cell morphology 59 32 frequent (33%) Frequent (79-30%) HP:0005561
6 abnormality of the gastrointestinal tract 59 32 occasional (7.5%) Occasional (29-5%) HP:0011024
7 fatigue 59 32 frequent (33%) Frequent (79-30%) HP:0012378
8 fever 59 32 frequent (33%) Frequent (79-30%) HP:0001945
9 b-cell lymphoma 59 32 hallmark (90%) Very frequent (99-80%) HP:0012191

GenomeRNAi Phenotypes related to Mantle Cell Lymphoma according to GeneCards Suite gene sharing:

26
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Increased cell death HMECs cells GR00103-A-0 9.63 BCL6 BMI1 CCND2 MDM2 MYC TP53
2 Increased viability with MLN4924 (a NAE inhibitor) GR00250-A-3 9.43 ATM BCL2 BMI1 MCL1 MDM2 TP53
3 Synthetic lethal with MLN4924 (a NAE inhibitor) GR00250-A-1 9.36 MCL1 TP53 ATM BCL2
4 Synthetic lethal with MLN4924 (a NAE inhibitor) GR00250-A-2 9.36 BTK CCND1 MCL1 MYC TP53 ATM

MGI Mouse Phenotypes related to Mantle Cell Lymphoma:

46 (show all 12)
# Description MGI Source Accession Score Top Affiliating Genes
1 cellular MP:0005384 10.24 ATM BCL2 BCL6 BTK CCND1 EZH2
2 hematopoietic system MP:0005397 10.22 ATM BCL2 BCL6 BTK CCND1 CCND2
3 cardiovascular system MP:0005385 10.21 MDM2 MYC SOX11 TP53 ATM BCL2
4 endocrine/exocrine gland MP:0005379 10.17 MCL1 MDM2 MYC SOX11 TP53 ATM
5 immune system MP:0005387 10.17 CCND1 CCND2 CD5 EZH2 MCL1 MDM2
6 homeostasis/metabolism MP:0005376 10.15 ATM BCL2 BCL6 BTK CCND1 CCND2
7 embryo MP:0005380 10.06 MDM2 MYC SOX11 TP53 ATM BCL2
8 integument MP:0010771 10.03 ATM BCL2 BTK CCND1 CD5 EZH2
9 digestive/alimentary MP:0005381 10.02 BCL2 BTK CCND1 MDM2 MYC SOX11
10 neoplasm MP:0002006 9.76 ATM BCL2 BTK CCND1 EZH2 MDM2
11 normal MP:0002873 9.61 BCL6 CCND1 CD5 EZH2 MCL1 MDM2
12 reproductive system MP:0005389 9.28 ATM BCL2 BCL6 CCND1 CCND2 MCL1

Drugs & Therapeutics for Mantle Cell Lymphoma

FDA approved drugs:

# Drug Name Active Ingredient(s) 18 Company Approval Date
1
Imbruvica 18 49 IBRUTINIB Pharmacyclics November of 2013/February 2014
2
Revlimid 18 49 LENALIDOMIDE Celgene June 2013
3
Velcade 18 49 BORTEZOMIB Millennium Pharmaceuticals May 2003

Drugs for Mantle Cell Lymphoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 498)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Cyclophosphamide Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 50-18-0, 6055-19-2 2907
2
Lenograstim Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 135968-09-1
3
Thiotepa Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 52-24-4 5453
4
Cisplatin Approved Phase 4,Phase 3,Phase 2,Phase 1 15663-27-1 84093 441203 2767
5
Cytarabine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable 147-94-4 6253
6
Dexamethasone Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 1,Phase 2,Early Phase 1,Not Applicable 50-02-2 5743
7
Doxorubicin Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 23214-92-8 31703
8
Etoposide Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable 33419-42-0 36462
9
Prednisone Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable 53-03-2 5865
10
rituximab Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 174722-31-7 10201696
11
Vincristine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable 2068-78-2, 57-22-7 5978
12
Miconazole Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable 22916-47-8 4189
13
Everolimus Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 159351-69-6 6442177
14
Sirolimus Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 53123-88-9 5284616 6436030 46835353
15
Doxil Approved June 1999 Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 31703
16 Alkylating Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
17 Antilymphocyte Serum Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
18 Antineoplastic Agents, Alkylating Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
19 Antirheumatic Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
20 Immunosuppressive Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
21 Angiogenesis Inhibitors Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable
22 Angiogenesis Modulating Agents Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable
23 Anti-Bacterial Agents Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable,Early Phase 1
24 Antibiotics, Antitubercular Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
25 Antiemetics Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable
26 Anti-Infective Agents Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable,Early Phase 1
27 Anti-Inflammatory Agents Phase 4,Phase 3,Phase 1,Phase 2,Early Phase 1,Not Applicable
28 Antimetabolites Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
29 Antimetabolites, Antineoplastic Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
30 Antimitotic Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable
31 Antineoplastic Agents, Hormonal Phase 4,Phase 3,Phase 1,Phase 2,Early Phase 1,Not Applicable
32 Antineoplastic Agents, Phytogenic Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable
33 Antiviral Agents Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable
34 Autonomic Agents Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable
35 BB 1101 Phase 4,Phase 3,Phase 1,Phase 2,Early Phase 1,Not Applicable
36 Dexamethasone acetate Phase 4,Phase 3,Phase 1,Phase 2,Early Phase 1,Not Applicable 1177-87-3
37 Etoposide phosphate Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable
38 Gastrointestinal Agents Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable
39 glucocorticoids Phase 4,Phase 3,Phase 1,Phase 2,Early Phase 1,Not Applicable
40 HIV Protease Inhibitors Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable
41 Hormone Antagonists Phase 4,Phase 3,Phase 1,Phase 2,Early Phase 1,Not Applicable
42 Hormones Phase 4,Phase 3,Phase 1,Phase 2,Early Phase 1,Not Applicable
43 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 4,Phase 3,Phase 1,Phase 2,Early Phase 1,Not Applicable
44 Peripheral Nervous System Agents Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable
45
protease inhibitors Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable
46 Topoisomerase Inhibitors Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
47 Antifungal Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable
48
Carmustine Approved, Investigational Phase 3,Phase 2,Phase 1,Not Applicable 154-93-8 2578
49
Melphalan Approved Phase 3,Phase 2,Phase 1,Not Applicable 148-82-3 4053 460612
50
Fludarabine Approved Phase 3,Phase 2,Phase 1,Not Applicable 21679-14-1, 75607-67-9 30751

Interventional clinical trials:

(show top 50) (show all 967)
# Name Status NCT ID Phase Drugs
1 An Open Label Treatment Use Protocol for Ibrutinib in Subjects With Relapsed or Refractory Mantle Cell Lymphoma Completed NCT01833039 Phase 4 Ibrutinib
2 Bone Marrow Transplantation in Treating Patients With Hematologic Cancer Completed NCT00003398 Phase 4 cyclophosphamide;thiotepa
3 EDOCH Alternating With DHAP for New Diagnosed Younger MCL Recruiting NCT02858804 Phase 4 Etoposide;Doxorubicin;Dexamethasone;Vincristine;Cyclophosphamide;Cytarabine;Cisplatin;Rituximab;Thalidomide;Prednisone
4 Comparison Of 2 Doses Of Temsirolimus (Torisel) In Patients With Mantle Cell Lymphoma Active, not recruiting NCT01180049 Phase 4 temsirolimus;temsirolimus
5 A Study to Assess Safety of ImbruvicaTM in Indian Participants With Chronic Lymphocytic Leukemia or Mantle Cell Lymphoma Who Have Received at Least One Prior Therapy or Chronic Lymphocytic Leukemia With 17p Deletion Not yet recruiting NCT03190330 Phase 4 Ibrutinib 420 mg;Ibrutinib 560 mg
6 Chemotherapy Followed by Radiation Therapy and Peripheral Stem Cell Transplant Compared With Chemotherapy Plus Interferon Alfa in Treating Patients With Stage III or Stage IV Mantle Cell Lymphoma Unknown status NCT00016887 Phase 3 carmustine;cyclophosphamide;cytarabine;dexamethasone;etoposide;melphalan
7 Fludarabine and Cyclophosphamide With or Without Rituximab in Treating Patients With Previously Untreated Mantle Cell Lymphoma Unknown status NCT00641095 Phase 3 cyclophosphamide;fludarabine phosphate
8 Efficacy of R-CHOP vs R-CHOP/R-DHAP in Untreated MCL Unknown status NCT00209222 Phase 3 Rituximab;Cyclophosphamide;Doxorubicin;Vincristine;Prednisone;Cisplatinum;Ara-C;Dexamethasone;BCNU;Melphalan;Etoposide;G-CSF
9 Ketamine Hydrochloride and Best Pain Management in Treating Cancer Patients With Neuropathic Pain Unknown status NCT01316744 Phase 3 ketamine hydrochloride
10 Early Hospital Discharge or Standard Inpatient Care in Cancer Patients Receiving Antibiotics for Febrile Neutropenia Unknown status NCT00445497 Phase 3 amoxicillin-clavulanate potassium;ciprofloxacin
11 Levofloxacin Compared With Cefepime in Treating Cancer Patients With Fever and Neutropenia Unknown status NCT00020865 Phase 3 cefepime hydrochloride;levofloxacin
12 Monoclonal Antibodies in Detecting Residual Disease in Patients Who Have Been Treated for Non-Hodgkin's Lymphoma Unknown status NCT00003338 Phase 2, Phase 3
13 Radiolabeled Monoclonal Antibody in the Detection and Staging of Patients With Non-Hodgkin's Lymphoma Unknown status NCT00003337 Phase 3
14 Combination Chemotherapy With or Without Idarubicin and Peripheral Stem Cell Transplantation in Treating Patients With Leukemia or Myelodysplastic Syndrome Unknown status NCT00002989 Phase 3 busulfan;cyclophosphamide;idarubicin;melphalan
15 Combination Chemotherapy Followed By Radiation Therapy in Treating Patients With Aggressive Non-Hodgkin's Lymphoma Unknown status NCT00053768 Phase 3 EPOCH regimen;cyclophosphamide;doxorubicin hydrochloride;etoposide;prednisone;vincristine sulfate
16 Combination Chemotherapy With or Without Rituximab in Treating Older Patients With Non-Hodgkin's Lymphoma Unknown status NCT00052936 Phase 3 CHOP regimen;cyclophosphamide;doxorubicin hydrochloride;prednisone;vincristine sulfate
17 Combination Chemotherapy Plus Filgrastim With or Without Rituximab in Treating Older Patients With Non-Hodgkin's Lymphoma Unknown status NCT00028717 Phase 3 cyclophosphamide;doxorubicin hydrochloride;prednisone;vincristine sulfate
18 Interferon Alfa-2b Following Chemotherapy and Peripheral Stem Cell Transplantation in Treating Patients With Recurrent or Refractory Hodgkin's Disease or Non-Hodgkin's Lymphoma Unknown status NCT00003924 Phase 3
19 Study of Ibrutinib (a Bruton's Tyrosine Kinase Inhibitor), Versus Temsirolimus in Patients With Relapsed or Refractory Mantle Cell Lymphoma Who Have Received at Least One Prior Therapy Completed NCT01646021 Phase 3 Ibrutinib;Temsirolimus
20 Study of the Combination of Rituximab, Cyclophosphamide, Doxorubicin, VELCADE, and Prednisone or Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Patients With Newly Diagnosed Mantle Cell Lymphoma Completed NCT00722137 Phase 3 Rituximab 375 mg/m^2;Cyclophosphamide 750 mg/m^2;Doxorubicin 50 mg/m^2;VELCADE 1.3 mg/m^2;Prednisone 100 mg/m^2;Vincristine 1.4 mg/m^2
21 Study of Bendamustine Hydrochloride and Rituximab (BR) Compared With R-CVP or R-CHOP in the First-Line Treatment of Patients With Advanced Indolent Non-Hodgkin's Lymphoma (NHL) or Mantle Cell Lymphoma (MCL) - Referred to as the BRIGHT Study Completed NCT00877006 Phase 3 bendamustine;rituximab;vincristine;prednisone;cyclophosphamide;doxorubicin
22 Study to Assess the Effect of Treatment With Bendamustine in Combination With Rituximab on QT Interval in Patients With Advanced Indolent Non-Hodgkin's Lymphoma (NHL) or Mantle Cell Lymphoma (MCL) Completed NCT01073163 Phase 3 Bendamustine;Rituximab
23 Monoclonal Antibody Therapy in Treating Patients With Follicular or Mantle Cell Lymphoma Completed NCT00003280 Phase 3
24 Study Evaluating Temsirolimus (CCI-779) In Mantle Cell Lymphoma (MCL) Completed NCT00117598 Phase 3 Temsirolimus (CCI-779);Temsirolimus (CCI-779);Investigator's choice
25 Bendamustine Plus Rituximab Versus Fludarabine Plus Rituximab Completed NCT01456351 Phase 3 Bendamustine plus Rituximab;Fludarabine 25 mg/m² d 1-3 + Rituximab 375 mg/m² d 1 q4w
26 Mantel Cell Lymphoma Efficacy of Rituximab Maintenance Completed NCT00921414 Phase 3 Rituximab
27 Bendamustine Plus Rituximab Versus CHOP Plus Rituximab Completed NCT00991211 Phase 3 Bendamustine;Standard chemotherapy CHOP + Ritiximab
28 A Study of MabThera (Rituximab) in Patients With Advanced Non-Hodgkin's Lymphoma Completed NCT00269113 Phase 3 rituximab [MabThera/Rituxan];Standard chemotherapy
29 Internet-Based Program With or Without Telephone-Based Problem-Solving Training in Helping Long-Term Survivors of Hematopoietic Stem Cell Transplant Cope With Late Complications Completed NCT00799461 Phase 3
30 Graft-Versus-Host Disease Prophylaxis in Treating Patients With Hematologic Malignancies Undergoing Unrelated Donor Peripheral Blood Stem Cell Transplant Completed NCT01231412 Phase 3 Cyclosporine;Fludarabine Phosphate;Mycophenolate Mofetil;Sirolimus
31 Total-Body Irradiation With or Without Fludarabine Phosphate Followed By Donor Stem Cell Transplant in Treating Patients With Hematologic Cancer Completed NCT00075478 Phase 3 Fludarabine Phosphate;Mycophenolate Mofetil;Cyclosporine
32 Personalized Information or Basic Information in Helping Patients Make Decisions About Participating in a Clinical Trial Completed NCT00750009 Phase 3
33 American Ginseng in Treating Patients With Fatigue Caused by Cancer Completed NCT00719563 Phase 3 American ginseng
34 Opioid Titration Order Sheet or Standard Care in Treating Patients With Cancer Pain Completed NCT00666211 Phase 3
35 Darbepoetin Alfa With or Without Iron in Treating Anemia Caused By Chemotherapy in Patients With Cancer Completed NCT00661999 Phase 3 sodium ferric gluconate complex in sucrose
36 Fentanyl Sublingual Spray in Treating Patients With Breakthrough Cancer Pain Completed NCT00538850 Phase 3 Fentanyl sublingual spray;Placebo
37 St. John's Wort in Relieving Fatigue in Patients Undergoing Chemotherapy or Hormone Therapy for Cancer Completed NCT00005805 Phase 3
38 Prevention of Infection in Patients With Hematologic Cancer and Persistent Fever Caused by a Low White Blood Cell Count Completed NCT00003805 Phase 3 piperacillin sodium;piperacillin-tazobactam;tazobactam sodium;vancomycin
39 Dalteparin to Prevent Complications in Cancer Patients Receiving Chemotherapy Through a Catheter Completed NCT00006083 Phase 3 Fragmin
40 Darbepoetin Alfa Compared With Epoetin Alfa in Treating Anemia in Patients Receiving Chemotherapy for Cancer Completed NCT00070382 Phase 3 darbepoetin alfa;epoetin alfa
41 Caspofungin Acetate Compared With Amphotericin B Liposomal in Treating Patients With Persistent Fever and Neutropenia Following Cancer Treatment Completed NCT00008359 Phase 3 caspofungin acetate;liposomal amphotericin B
42 Levofloxacin to Prevent Infection Following Chemotherapy in Treating Patients With Solid Tumors or Lymphoma Completed NCT00005590 Phase 3 levofloxacin
43 Liposomal Amphotericin B in Treating Granulocytopenia and Persistent Unexplained Fever in Cancer Patients Completed NCT00003938 Phase 3 liposomal amphotericin B
44 Epoetin Alfa in Treating Anemia in Patients With Lymphoma, Chronic Lymphocytic Leukemia, or Multiple Myeloma and Anemia Caused By Chemotherapy Completed NCT00003341 Phase 3
45 Music Therapy or Book Discussion in Improving Quality of Life in Young Patients Undergoing Stem Cell Transplant Completed NCT00305851 Phase 3
46 Laboratory-Treated Donor Bone Marrow in Treating Patients Who Are Undergoing a Donor Bone Marrow Transplant for Hematologic Cancer Completed NCT00265837 Phase 3
47 Rituximab and Combination Chemotherapy in Treating Patients With Non-Hodgkin's Lymphoma Completed NCT00278421 Phase 3 cyclophosphamide;doxorubicin hydrochloride;prednisone;vincristine sulfate
48 Rituximab and Combination Chemotherapy With or Without Radiation Therapy in Treating Patients With B-Cell Non-Hodgkin's Lymphoma Completed NCT00278408 Phase 3 cyclophosphamide;doxorubicin hydrochloride;prednisone;vincristine sulfate
49 Captopril in Treating Patients Undergoing Bone Marrow or Stem Cell Transplantation Completed NCT00004230 Phase 3 captopril;cyclophosphamide
50 Ribavirin With or Without Monoclonal Antibody Therapy in Treating Patients Who Develop RSV Pneumonia Following Peripheral Stem Cell Transplantation Completed NCT00014391 Phase 3 ribavirin

Search NIH Clinical Center for Mantle Cell Lymphoma

Inferred drug relations via UMLS 73 / NDF-RT 51 :


Cell-based therapeutics:


LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database
Read about Mantle Cell Lymphoma cell therapies at LifeMap Discovery.

Cochrane evidence based reviews: lymphoma, mantle-cell

Genetic Tests for Mantle Cell Lymphoma

Genetic tests related to Mantle Cell Lymphoma:

# Genetic test Affiliating Genes
1 Mantle Cell Lymphoma 29

Anatomical Context for Mantle Cell Lymphoma

MalaCards organs/tissues related to Mantle Cell Lymphoma:

41
B Cells, Bone, Bone Marrow, T Cells, Kidney, Liver, Lymph Node

Publications for Mantle Cell Lymphoma

Articles related to Mantle Cell Lymphoma:

(show top 50) (show all 1131)
# Title Authors Year
1
Italian real life experience with ibrutinib: results of a large observational study on 77 relapsed/refractory mantle cell lymphoma. ( 29805746 )
2018
2
Phase I trial of rituximab, cladribine, and temsirolimus (RCT) for initial therapy of mantle cell lymphoma. ( 29390098 )
2018
3
The B cell receptor signaling pathway in mantle cell lymphoma. ( 29861875 )
2018
4
Gastrointestinal involvement by mantle cell lymphoma identified by biopsy performed during endoscopy: A case report. ( 29419676 )
2018
5
Wogonin Inhibits Growth of Mantle Cell Lymphoma Cells through Nuclear Factor-I_B Signaling Pathway. ( 29451160 )
2018
6
Spontaneous regression of mantle cell lymphoma: a report of four cases. ( 29843782 )
2018
7
Population-based study of mantle cell lymphoma: Improvements in survival only seen in younger patients. ( 29363157 )
2018
8
Mantle Cell Lymphoma with a Single Protruding Lesion as the Cause of Intussusception. ( 29434133 )
2018
9
In vitro and in vivo activity of a new small-molecule inhibitor of HDAC6 in mantle cell lymphoma. ( 29880608 )
2018
10
Understanding resistance mechanisms to BTK and BCL2 inhibitors in mantle cell lymphoma: implications for design of clinical trials. ( 29912596 )
2018
11
Dihydrocelastrol exerts potent antitumor activity in mantle cell lymphoma cells via dual inhibition of mTORC1 and mTORC2. ( 29901111 )
2018
12
Cyclin D1 mRNA as a molecular marker for minimal residual disease monitoring in patients with mantle cell lymphoma. ( 29273915 )
2018
13
Immunophenotypic Variations in Mantle Cell Lymphoma and Their Impact on Clinical Behavior and Outcome. ( 29869903 )
2018
14
Successful use of cytarabine and bendamustine in a patient with mantle cell lymphoma and acute renal failure using intermittent hemodialysis: A case report. ( 29385883 )
2018
15
Deferred treatment is a safe and viable option for selected patients with mantle cell lymphoma. ( 29912594 )
2018
16
Lenalidomide plus bendamustine-rituximab does not overcome the adverse impact of TP53 mutations in mantle cell lymphoma. ( 29794145 )
2018
17
Allogeneic hematopoietic cell transplantation is potentially curative in mantle cell lymphoma: results from a single institution study. ( 29963932 )
2018
18
NF-I_B signaling and its relevance to the treatment of mantle cell lymphoma. ( 29907126 )
2018
19
Rac1 is a novel therapeutic target in mantle cell lymphoma. ( 29434202 )
2018
20
MiR-199a mediated the dissemination of human mantle cell lymphoma by interacting with the CCR7/CCL21 pair. ( 29979193 )
2018
21
Cirmtuzumab inhibits ibrutinib-resistant, Wnt5a-induced Rac1 activation and proliferation in mantle cell lymphoma. ( 29872501 )
2018
22
Mantle Cell Lymphoma with t(11;22) (q13;q11.2) an indolent clinical variant? ( 29415598 )
2018
23
Combining Ibrutinib with Chk1 Inhibitors Synergistically Targets Mantle Cell Lymphoma Cell Lines. ( 29441438 )
2018
24
Commentary on: Survival benefit of mantle cell lymphoma patients enrolled in clinical trials; a joint study from the LYSA group and French cancer registries. ( 29380057 )
2018
25
Can we improve on ibrutinib in mantle cell lymphoma? ( 29396093 )
2018
26
Cryptococcal meningoencephalitis in patients with mantle cell lymphoma on ibrutinib. ( 29910833 )
2018
27
Early Generated B-1-Derived B Cells Have the Capacity To Progress To Become Mantle Cell Lymphoma-like Neoplasia in Aged Mice. ( 29898964 )
2018
28
Venetoclax as a single agent and in combination with PI3K-MTOR1/2 kinase inhibitors against ibrutinib sensitive and resistant mantle cell lymphoma. ( 29383700 )
2018
29
Targeting the PI3K/Akt/mTOR signaling pathway by pterostilbene attenuates mantle cell lymphoma progression. ( 29961897 )
2018
30
R-High-CHOP/CHASER/LEED with AutologousA Stem Cell Transplantation in Newly DiagnosedA Mantle Cell Lymphoma: JCOG0406. ( 29957865 )
2018
31
Current trials for frontline therapy of mantle cell lymphoma. ( 29374487 )
2018
32
Multi-center phase II trial of bortezomib and rituximab maintenance combination therapy in patients with mantle cell lymphoma after consolidative autologous stem cell transplantation. ( 29954415 )
2018
33
Ibrutinib, lenalidomide, and rituximab in relapsed or refractory mantle cell lymphoma (PHILEMON): a multicentre, open-label, single-arm, phase 2 trial. ( 29396091 )
2018
34
Promising efficacy of novel BTK inhibitor AC0010 in mantle cell lymphoma. ( 29392403 )
2018
35
Frontline Treatment for Older Patients with Mantle Cell Lymphoma. ( 29895632 )
2018
36
Mixed-species RNAseq analysis of human lymphoma cells adhering to mouse stromal cells identifies a core gene set that is also differentially expressed in the lymph node microenvironment of mantle cell lymphoma and chronic lymphocytic leukemia patients. ( 29449436 )
2018
37
A British Society for haematology good practice paper on the diagnosis and investigation of patients with mantle cell lymphoma. ( 29882587 )
2018
38
CD40L mediated alternative NFI_B-signaling induces resistance to BCR-inhibitors in patients with mantle cell lymphoma. ( 29367645 )
2018
39
Current Approaches to Mantle Cell Lymphoma: Diagnosis, Prognosis, and Therapies. ( 28561694 )
2017
40
Early-stage mantle cell lymphoma: a retrospective analysis from the International Lymphoma Radiation Oncology Group (ILROG). ( 28911068 )
2017
41
Orbital mantle cell lymphoma presenting as myasthenia gravis. ( 28820310 )
2017
42
Hyperfractionated Cyclophosphamide, Vincristine, Doxorubicin, and Dexamethasone Chemotherapy in Mantle Cell Lymphoma Patients Is Associated with Higher Rates of Hematopoietic Progenitor Cell Mobilization Failure despite Plerixafor Rescue. ( 28434928 )
2017
43
SOX11 promotes tumor protective microenvironment interactions through CXCR4 and FAK regulation in mantle cell lymphoma. ( 28533307 )
2017
44
Cyclin D1 depletion induces DNA damage in mantle cell lymphoma lines. ( 27338091 )
2017
45
Mantle Cell Lymphoma Presenting as a Subcutaneous Soft Tissue Mass With an Unusual Appearance. ( 28081018 )
2017
46
Antineutrophil cytoplasmic antibody-positive pauci-immune glomerulonephritis associated with mantle cell lymphoma. ( 29043141 )
2017
47
Second-line rituximab, lenalidomide, and bendamustine (R2B) in mantle cell lymphoma: a phase 2 clinical trial of the Fondazione Italiana Linfomi. ( 28082342 )
2017
48
Cyclin D1-negative blastoid mantle cell lymphoma exhibiting cleaved to bilobated cytomorphology. ( 28495928 )
2017
49
Correction: ROS-Induced CXCR4 Signaling Regulates Mantle Cell Lymphoma (MCL) Cell Survival and Drug Resistance in the Bone Marrow Microenvironment via Autophagy. ( 28373366 )
2017
50
Synergistic Cytotoxicity of Lenalidomide and Dexamethasone in Mantle Cell Lymphoma via Cereblon-dependent Targeting of the IL-6/STAT3/PI3K Axis. ( 28529032 )
2017

Variations for Mantle Cell Lymphoma

ClinVar genetic disease variations for Mantle Cell Lymphoma:

6
# Gene Variation Type Significance SNP ID Assembly Location
1 ATM NM_000051.3(ATM): c.7268A> G (p.Glu2423Gly) single nucleotide variant Pathogenic rs121434221 GRCh37 Chromosome 11, 108199926: 108199926
2 ATM NM_000051.3(ATM): c.7268A> G (p.Glu2423Gly) single nucleotide variant Pathogenic rs121434221 GRCh38 Chromosome 11, 108329199: 108329199
3 ATM NM_000051.3(ATM): c.7251_7253dupGAA (p.Lys2418_Arg2419insLys) duplication Pathogenic rs796051857 GRCh38 Chromosome 11, 108329182: 108329184
4 ATM NM_000051.3(ATM): c.7251_7253dupGAA (p.Lys2418_Arg2419insLys) duplication Pathogenic rs796051857 GRCh37 Chromosome 11, 108199909: 108199911
5 ATM NM_000051.3(ATM): c.4081C> T (p.Gln1361Ter) single nucleotide variant Pathogenic rs121434222 GRCh37 Chromosome 11, 108158414: 108158414
6 ATM NM_000051.3(ATM): c.4081C> T (p.Gln1361Ter) single nucleotide variant Pathogenic rs121434222 GRCh38 Chromosome 11, 108287687: 108287687

Cosmic variations for Mantle Cell Lymphoma:

9
(show top 50) (show all 362)
# Cosmic Mut ID Gene Symbol COSMIC Disease Classification
(Primary site, Site subtype, Primary histology, Histology subtype)
Mutation CDS Mutation AA GRCh38 Location Conf
1 COSM3733325 ZNF296 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,mantle cell lymphoma c.488G>A p.G163D 19:45072541-45072541 7
2 COSM212352 ZFHX3 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,mantle cell lymphoma c.4136C>T p.T1379M 16:72798546-72798546 7
3 COSM3733324 UBR5 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,mantle cell lymphoma c.6190G>A p.E2064K 8:102278924-102278924 7
4 COSM3733267 UBR5 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,mantle cell lymphoma c.8147C>G p.S2716* 8:102257672-102257672 7
5 COSM44687 TP53 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,mantle cell lymphoma c.379T>C p.S127P 17:7675233-7675233 7
6 COSM10662 TP53 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,mantle cell lymphoma c.743G>A p.R248Q 17:7674220-7674220 7
7 COSM10705 TP53 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,mantle cell lymphoma c.586C>T p.R196* 17:7674945-7674945 7
8 COSM11450 TP53 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,mantle cell lymphoma c.644G>T p.S215I 17:7674887-7674887 7
9 COSM44309 TP53 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,mantle cell lymphoma c.440T>G p.V147G 17:7675172-7675172 7
10 COSM10749 TP53 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,mantle cell lymphoma c.830G>T p.C277F 17:7673790-7673790 7
11 COSM10659 TP53 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,mantle cell lymphoma c.817C>T p.R273C 17:7673803-7673803 7
12 COSM43651 TP53 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,mantle cell lymphoma c.763A>T p.I255F 17:7674200-7674200 7
13 COSM43826 TP53 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,mantle cell lymphoma c.706T>A p.Y236N 17:7674257-7674257 7
14 COSM43814 TP53 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,mantle cell lymphoma c.587G>C p.R196P 17:7674944-7674944 7
15 COSM10724 TP53 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,mantle cell lymphoma c.839G>C p.R280T 17:7673781-7673781 7
16 COSM10648 TP53 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,mantle cell lymphoma c.524G>A p.R175H 17:7675088-7675088 7
17 COSM44467 TP53 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,mantle cell lymphoma c.497C>G p.S166* 17:7675115-7675115 7
18 COSM11089 TP53 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,mantle cell lymphoma c.584T>C p.I195T 17:7674947-7674947 7
19 COSM10656 TP53 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,mantle cell lymphoma c.742C>T p.R248W 17:7674221-7674221 7
20 COSM44962 TP53 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,mantle cell lymphoma c.774A>T p.E258D 17:7674189-7674189 7
21 COSM11123 TP53 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,mantle cell lymphoma c.838A>G p.R280G 17:7673782-7673782 7
22 COSM44571 TP53 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,mantle cell lymphoma c.581T>G p.L194R 17:7674950-7674950 7
23 COSM10660 TP53 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,mantle cell lymphoma c.818G>A p.R273H 17:7673802-7673802 7
24 COSM10667 TP53 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,mantle cell lymphoma c.646G>A p.V216M 17:7674885-7674885 7
25 COSM6901 TP53 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,mantle cell lymphoma c.559+1G>A p.? 17:7675052-7675052 7
26 COSM44972 TP53 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,mantle cell lymphoma c.831T>A p.C277* 17:7673789-7673789 7
27 COSM43846 TP53 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,mantle cell lymphoma c.487T>C p.Y163H 17:7675125-7675125 7
28 COSM10786 TP53 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,mantle cell lymphoma c.949C>T p.Q317* 17:7673579-7673579 7
29 COSM10883 TP53 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,mantle cell lymphoma c.731G>A p.G244D 17:7674232-7674232 7
30 COSM11114 TP53 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,mantle cell lymphoma c.528C>G p.C176W 17:7675084-7675084 7
31 COSM10758 TP53 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,mantle cell lymphoma c.659A>G p.Y220C 17:7674872-7674872 7
32 COSM6987278 TGFBR1 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,mantle cell lymphoma c.782G>A p.G261E 9:99138066-99138066 7
33 COSM6987493 STAT3 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,mantle cell lymphoma c.724G>T p.D242Y 17:42337508-42337508 7
34 COSM3733439 SMC1A haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,mantle cell lymphoma c.2398C>G p.Q800E 23:53403588-53403588 7
35 COSM3733438 SMC1A haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,mantle cell lymphoma c.2400G>T p.Q800H 23:53403586-53403586 7
36 COSM3733287 SMARCA4 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,mantle cell lymphoma c.4600C>A p.Q1534K 19:11058854-11058854 7
37 COSM3733280 SMARCA4 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,mantle cell lymphoma c.3724G>T p.E1242* 19:11033467-11033467 7
38 COSM3733500 SMARCA4 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,mantle cell lymphoma c.3565C>G p.R1189G 19:11033308-11033308 7
39 COSM3733331 SMARCA4 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,mantle cell lymphoma c.2897G>A p.R966Q 19:11023555-11023555 7
40 COSM3733266 SMARCA4 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,mantle cell lymphoma c.3186C>G p.H1062Q 19:11026317-11026317 7
41 COSM3733301 SMARCA4 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,mantle cell lymphoma c.2641G>A p.D881N 19:11021749-11021749 7
42 COSM3733382 SMARCA4 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,mantle cell lymphoma c.3109A>T p.N1037Y 19:11025449-11025449 7
43 COSM3733285 SI haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,mantle cell lymphoma c.1825T>C p.W609R 3:165046903-165046903 7
44 COSM3733321 SI haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,mantle cell lymphoma c.1126C>T p.R376W 3:165059922-165059922 7
45 COSM3733430 SALL3 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,mantle cell lymphoma c.3044C>T p.S1015F 18:78995035-78995035 7
46 COSM3733372 ROBO2 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,mantle cell lymphoma c.2083C>T p.R695* 3:77574610-77574610 7
47 COSM3733347 ROBO2 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,mantle cell lymphoma c.964G>A p.D322N 3:77546367-77546367 7
48 COSM3733492 RB1 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,mantle cell lymphoma c.1535T>A p.L512* 13:48381283-48381283 7
49 COSM171725 RB1 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,mantle cell lymphoma c.838G>T p.E280* 13:48362934-48362934 7
50 COSM3733293 RB1 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,mantle cell lymphoma c.2570G>T p.R857L 13:48476750-48476750 7

Copy number variations for Mantle Cell Lymphoma from CNVD:

7 (show all 39)
# CNVD ID Chromosom Start End Type Gene Symbol CNVD Disease
1 44978 10 6600000 12200000 Loss Mantle cell lymphoma
2 49103 11 102900000 110400000 Loss ACAT Mantle cell lymphoma
3 49104 11 102900000 110400000 Loss ATM Mantle cell lymphoma
4 49105 11 102900000 110400000 Loss CUL5 Mantle cell lymphoma
5 49106 11 102900000 110400000 Loss FDX1 Mantle cell lymphoma
6 49107 11 102900000 110400000 Loss NPAT Mantle cell lymphoma
7 49108 11 102900000 110400000 Loss RAB39 Mantle cell lymphoma
8 49703 11 110400000 112500000 Loss Mantle cell lymphoma
9 49990 11 112500000 114500000 Loss TMPRSS5 Mantle cell lymphoma
10 49991 11 112500000 114500000 Loss USP28 Mantle cell lymphoma
11 49992 11 112500000 114500000 Loss ZW10 Mantle cell lymphoma
12 54401 11 43500000 48800000 Loss TP53I11 Mantle cell lymphoma
13 60881 11 92800000 97200000 Loss MAML2 Mantle cell lymphoma
14 61262 11 97200000 102100000 Loss BIRC2 Mantle cell lymphoma
15 61263 11 97200000 102100000 Loss BIRC3 Mantle cell lymphoma
16 74176 13 101700000 104800000 Loss BIVM Mantle cell lymphoma
17 74177 13 101700000 104800000 Loss ERCC5 Mantle cell lymphoma
18 74178 13 101700000 104800000 Loss KDELC1 Mantle cell lymphoma
19 74694 13 110300000 115169878 Loss C13orf11 Mantle cell lymphoma
20 74695 13 110300000 115169878 Loss C13orf17 Mantle cell lymphoma
21 74696 13 110300000 115169878 Loss CUL4A Mantle cell lymphoma
22 74697 13 110300000 115169878 Loss GRTP1 Mantle cell lymphoma
23 74698 3 117011831 117647068 Loss LAMP Mantle cell lymphoma
24 74699 13 110300000 115169878 Loss TFDP1 Mantle cell lymphoma
25 77990 13 48877883 49056026 Deletion RB1 Mantle cell lymphoma
26 79883 13 79000000 95000000 Copy number miR-17-92 Mantle cell lymphoma
27 80925 13 99300000 101700000 Loss PCCA Mantle cell lymphoma
28 118115 17 7571720 7590868 Mutation P53 Mantle cell lymphoma
29 141432 2 210288771 210598834 Deletion MAP2 Mantle cell lymphoma
30 143512 2 237300000 243199373 Loss Mantle cell lymphoma
31 170852 3 160700000 167600000 Loss SLITRK3 Mantle cell lymphoma
32 245172 9 102600000 108200000 Loss INVS Mantle cell lymphoma
33 248837 9 137400000 141213431 Loss TRAF2 Mantle cell lymphoma
34 250734 9 21967751 21994490 Deletion CDKN2A Mantle cell lymphoma
35 252714 9 36300000 38400000 Loss MELK Mantle cell lymphoma
36 254747 9 68700000 72200000 Loss TJP2 Mantle cell lymphoma
37 256309 9 91800000 93900000 Loss DIRAS2 Mantle cell lymphoma
38 256992 9 99300000 102600000 Loss GPR51 Mantle cell lymphoma
39 256993 9 99300000 102600000 Loss TBC1D2 Mantle cell lymphoma

Expression for Mantle Cell Lymphoma

Search GEO for disease gene expression data for Mantle Cell Lymphoma.

Pathways for Mantle Cell Lymphoma

Pathways related to Mantle Cell Lymphoma according to GeneCards Suite gene sharing:

(show top 50) (show all 67)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
12.97 ATM BCL2 CCND1 CCND2 MCL1 MDM2
2
Show member pathways
12.88 BCL2 CCND1 MDM2 MYC TP53
3 12.87 BCL2 CCND1 CCND2 MDM2 MYC TP53
4
Show member pathways
12.84 ATM BCL2 MCL1 MDM2 MYC TP53
5
Show member pathways
12.8 ATM BCL2 CCND1 CCND2 MDM2 TP53
6
Show member pathways
12.73 ATM BCL2 CCND1 MDM2 MYC TP53
7
Show member pathways
12.68 BCL2 CCND1 CCND2 MCL1 MYC
8
Show member pathways
12.58 ATM CCND1 CCND2 MDM2 MYC TP53
9 12.55 ATM CCND1 CCND2 MDM2 TP53
10
Show member pathways
12.49 BCL2 CCND1 CCND2 MYC
11
Show member pathways
12.49 CCND1 MDM2 MYC TP53
12 12.46 ATM CCND1 CCND2 MYC TP53
13
Show member pathways
12.45 ATM BCL2 MDM2 TP53
14
Show member pathways
12.37 ATM CCND1 CCND2 TP53
15 12.36 ATM CCND1 CCND2 MDM2 MYC TP53
16 12.31 BCL2 MDM2 MYC TP53
17 12.31 CCND1 MDM2 MYC TP53
18 12.31 CCND1 CCND2 MDM2 TP53
19
Show member pathways
12.26 ATM BCL2 CCND1 MDM2 TP53
20
Show member pathways
12.23 ATM BCL2 CCND1 CCND2 MDM2 MIR16-1
21 12.21 CCND1 CCND2 MYC TP53
22 12.18 ATM CCND1 CCND2 MDM2 MYC TP53
23 12.18 ATM BCL6 BMI1 CCND2 MDM2 MYC
24 12.17 BCL2 CCND1 MDM2 MYC TP53
25 12.14 ATM BCL2 CCND1 MDM2 MYC TP53
26
Show member pathways
12.11 BCL2 BTK CCND2 MYC
27
Show member pathways
12.11 ATM BCL6 CCND1 CCND2 MDM2
28
Show member pathways
12.08 CCND1 CCND2 MYC
29 12.08 ATM BCL2 MDM2 TP53
30 12.08 BCL2 BCL6 MCL1 MDM2 TP53
31
Show member pathways
12.05 CCND1 CCND2 MDM2 MYC TP53
32 12.03 CCND1 MDM2 MYC TP53
33 12.01 CCND1 MDM2 MYC TP53
34 11.98 BCL2 BMI1 MDM2 TP53
35 11.97 BCL2 BCL6 CCND1 MCL1 MYC TP53
36 11.91 BCL2 CCND1 MYC TP53
37
Show member pathways
11.9 BCL2 BTK MYC
38 11.89 ATM BCL2 BTK
39 11.87 CCND1 MDM2 MYC TP53
40
Show member pathways
11.84 ATM MDM2 TP53
41 11.84 ATM BCL2 BMI1 CCND1 CCND2 EZH2
42 11.82 BMI1 CCND2 MYC TP53
43 11.8 CCND1 CCND2 MYC
44 11.79 BCL2 CCND1 MYC
45 11.77 CCND1 MDM2 MYC TP53
46 11.76 ATM MCL1 MYC
47
Show member pathways
11.76 ATM MDM2 TP53
48 11.76 ATM BCL2 MDM2 TP53
49
Show member pathways
11.72 BCL2 CCND2 MYC
50 11.71 ATM MYC TP53

GO Terms for Mantle Cell Lymphoma

Cellular components related to Mantle Cell Lymphoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 nucleoplasm GO:0005654 9.36 ATM BCL2 BCL6 BMI1 CCND1 CCND2

Biological processes related to Mantle Cell Lymphoma according to GeneCards Suite gene sharing:

(show all 36)
# Name GO ID Score Top Affiliating Genes
1 regulation of apoptotic process GO:0042981 9.99 ATM BCL2 BCL6 MCL1 TP53
2 negative regulation of gene expression GO:0010629 9.93 EZH2 MDM2 MYC SOX11
3 cellular response to DNA damage stimulus GO:0006974 9.88 ATM BCL2 BCL6 CCND1 MYC TP53
4 regulation of cell cycle GO:0051726 9.86 ATM BCL2 CCND1 CCND2
5 response to estradiol GO:0032355 9.85 CCND1 EZH2 MYC
6 DNA damage response, signal transduction by p53 class mediator resulting in cell cycle arrest GO:0006977 9.8 ATM MDM2 TP53
7 negative regulation of apoptotic process GO:0043066 9.8 BCL2 BCL6 CCND2 MCL1 MDM2 MYC
8 intrinsic apoptotic signaling pathway in response to DNA damage GO:0008630 9.78 ATM BCL2 MCL1
9 cellular response to hypoxia GO:0071456 9.78 BCL2 MDM2 MYC TP53
10 negative regulation of G1/S transition of mitotic cell cycle GO:2000134 9.77 BCL2 EZH2 MIR16-1
11 regulation of gene expression GO:0010468 9.77 BCL2 BMI1 EZH2 MDM2 MYC
12 positive regulation of cell cycle GO:0045787 9.76 CCND1 MDM2 MYC
13 cellular response to organic substance GO:0071310 9.75 BCL2 CCND1 MDM2
14 ovarian follicle development GO:0001541 9.74 ATM BCL2 MYC
15 response to steroid hormone GO:0048545 9.72 BCL2 CCND1 MDM2
16 liver regeneration GO:0097421 9.71 CCND1 EZH2 MYC
17 positive regulation of intrinsic apoptotic signaling pathway GO:2001244 9.69 BCL2 MIR16-1 TP53
18 cellular response to estrogen stimulus GO:0071391 9.67 MDM2 MYC
19 regulation of mitochondrial membrane permeability GO:0046902 9.66 BCL2 TP53
20 determination of adult lifespan GO:0008340 9.66 ATM TP53
21 response to magnesium ion GO:0032026 9.65 CCND1 MDM2
22 oocyte development GO:0048599 9.65 ATM BCL2
23 positive regulation of response to DNA damage stimulus GO:2001022 9.65 ATM MYC
24 cellular response to X-ray GO:0071481 9.64 ATM CCND2
25 positive regulation of histone deacetylation GO:0031065 9.64 BCL6 TP53
26 mitotic G1 DNA damage checkpoint GO:0031571 9.63 CCND1 TP53
27 response to gamma radiation GO:0010332 9.63 BCL2 MYC TP53
28 re-entry into mitotic cell cycle GO:0000320 9.61 CCND1 MYC
29 cellular response to gamma radiation GO:0071480 9.61 ATM MDM2 TP53
30 response to iron ion GO:0010039 9.5 BCL2 CCND1 MDM2
31 cellular response to actinomycin D GO:0072717 9.49 MDM2 TP53
32 cytokine-mediated signaling pathway GO:0019221 9.43 BCL2 BCL6 CCND1 MCL1 MYC TP53
33 replicative senescence GO:0090399 9.33 ATM MME TP53
34 negative regulation of transcription by RNA polymerase II GO:0000122 9.23 BCL6 BMI1 CCND1 EZH2 MDM2 MYC
35 cell proliferation GO:0008283 10.02 BCL2 CD5 MYC SOX11 TP53
36 positive regulation of cell proliferation GO:0008284 10 BCL2 CCND1 CCND2 MDM2 MYC SOX11

Molecular functions related to Mantle Cell Lymphoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 BH3 domain binding GO:0051434 8.96 BCL2 MCL1
2 promoter-specific chromatin binding GO:1990841 8.8 BMI1 EZH2 TP53

Sources for Mantle Cell Lymphoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....